UK Clears Elanco's $135M Divestiture For Bayer Deal
The U.K.'s antitrust regulator on Tuesday greenlighted the sale of Elanco Animal Health Inc.'s global rights for dog ear infection treatment Osurnia to Dechra Pharmaceuticals PLC for $135 million, just one...To view the full article, register now.
Already a subscriber? Click here to view full article